Health-related quality of life in high-grade glioma patients

Chinese Journal of Cancer

Volumn 33, Issue 1, 2014, Pages 40-45

  Dirven, Linda ^a   Aaronson, Neil K ^b   Heimans, Jan J ^a   Taphoorn, Martin J B ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

Brain tumors; Glioma; Health related quality of life; Patient reported outcome

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DEXAMETHASONE; ETIRACETAM; LOMUSTINE; OXCARBAZEPINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PRACTICE; COGNITION; CONSCIOUSNESS DISORDER; DISEASE SEVERITY; DROWSINESS; EPILEPSY; GASTROINTESTINAL DISEASE; GLIOMA; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE POLICY; HUMAN; LOSS OF APPETITE; MENTAL DISEASE; MOTOR DYSFUNCTION; MUSCLE ATROPHY; MUSCLE WEAKNESS; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

BRAIN NEOPLASMS; GLIOMA; HEALTH STATUS; HUMANS; NEOPLASM GRADING; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84891703978     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10214     Document Type: Article

References (50)

1. Ricard D, Idbaih A, Ducray F, et al. Primary brain tumours in adults. Lancet, 2012,379:1984-1996.
2. Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet, 2013,361:323-331.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005,352:987-996.
4. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology, 2000,54:1442-1448.
5. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol, 2002,20:2076-2084.
6. Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res, 2011,17:4588-4599.
7. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 2009,10:459-466.
8. Aaronson NK, Taphoorn MJ, Heimans JJ, et al. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol, 2011,29:4430-4435.
9. Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol, 2005,6:937-944.
10. Taphoorn MJ, van den Bent MJ, Mauer ME, et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol, 2007,25:5723-5730.
11. Aaronson NK. Quality of life: what is it? How should it be measured? Oncology (Williston Park), 1988,2:69-76.
12. US Department of Health and Human Services Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009 December. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM193282.pdf. [Accessed 29 October 2013].
13. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993,85:365-376.
14. Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res, 1996,5:139-150.
15. Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual. 3rd edition. Brussels: European Organization for Research and Treatment of Cancer. 2001.
16. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol, 1998,16:139-144.
17. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol, 1993,11:570-579.
18. Weitzner MA, Meyers CA, Gelke CK, et al. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer, 1995,75: 1151-1161.
19. Yost KJ, Eton DT. Combining distribution-and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof, 2005,28:172-191.
20. Cleeland CS, Mendoza TR, Wang XS. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer, 2000,89:1634-1646.
21. Armstrong TS, Mendoza T, Gning I, et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol, 2006,80:27-35.
22. Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat, 2004,14:73-96.
23. Giovagnoli AR. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour. J Neurol Neurosurg Psychiatry, 1999,67:358-363.
24. Salo J, Niemela A, Joukamaa M, et al. Effect of brain tumour laterality on patients' perceived quality of life. J Neurol Neurosurg Psychiatry, 2002,72:373-377.
25. Klein M, Engelberts NH, van der Ploeg HM, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol, 2003,54:514-520.
26. Bosma I, Reijneveld JC, Douw L, et al. Health-related quality of life of long-term high-grade glioma survivors. Neuro Oncol, 2009,11:51-58.
27. Yavas C, Zorlu F, Ozyigit G, et al. Health-related quality of life in high-grade glioma patients: a prospective single-center study. Support Care Cancer, 2012,20:2315-2325.
28. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol, 2004,3:159-168.
29. Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurg, 2005,57:495-504.
30. Jakola AS, Gulati S, Weber C, et al. Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study. PLoS One, 2011,6:e28592.
31. Jakola AS, Unsgard G, Solheim O. Quality of life in patients with intracranial gliomas: the impact of modern image-guided surgery. J Neurosurg, 2011,114:1622-1630.
32. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet, 2005,366:985-990.
33. Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer, 1998,34:1902-1909.
34. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol, 2009,8:810-818.
35. Postma TJ, Klein M, Verstappen CC, et al. Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology, 2002,59:121-123.
36. Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet, 2002,360:1361-1368.
37. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med, 2007,356:1527-1535.
38. Ernst-Stecken A, Ganslandt O, Lambrecht U, et al. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol, 2007,81:287-294.
39. Osoba D, Brada M, Yung WK, et al. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol, 2000,18:1481-1491.
40. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol, 2006,24:2715-2722.
41. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol, 2013,31:344-350.
42. Reddy K, Gaspar LE, Kavanagh BD, et al. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. J Neurooncol, 2013,114:111-116.
43. Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglio. Neuro Oncol, 2012,14(Suppl 6):vi101-vi105.
44. Gilbert MR, Dignam J, Won M, et al. Phase III double-blind placebo-controlled evaluating Bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol, 2013,31 Suppl:abstr 1.
45. Maschio M, Dinapoli L, Sperati F, et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol, 2011,104:205-214.
46. Maschio M, Dinapoli L, Sperati F, et al. Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. J Neurooncol, 2012,106:651-656.
47. Kaal EC, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol, 2004,16:593-600.
48. Osoba D, Bezjak A, Brundage M, et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer, 2005,41:280-287.
49. Dirven L, Reijneveld JC, Aaronson NK, et al. Health-related quality of life in patients with brain tumors: limitations and additional outcome measures. Curr Neurol Neurosci Rep, 2013,13:359.
50. Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA, 2002,288:3027-3034.